A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Enterome
- 入组人数
- 70
- 试验地点
- 12
- 主要终点
- Treatment-Emergent Serious Adverse Events Assessment
研究概览
简要总结
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
详细描述
EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Inclusion Criteria:
- •For inclusion in Cohort 1 patients should have adrenocortical carcinoma(ACC), or malignant pheochromocytoma/paraganglioma (MPP), as defined below for Cohorts 2A and 3A.
- •For inclusion in Cohorts 2A and 2B patients should have histologically confirmed (at primary diagnosis) unresectable locally advanced or metastatic adrenocortical carcinoma.
- •For inclusion in Cohorts 3A and 3B patients should have histologically confirmed (at primary diagnosis) unresectable malignant (defined as metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin organs) pheochromocytoma/paraganglioma, and RECIST defined progression should have been documented during a maximum of an 18-months period.
- •Patients with an age ≥ 18 years old.
- •Patients who are human leukocyte antigen (HLA)-A2 positive.
- •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Patients with a life expectancy > 4 months as judged by their treating physician.
- •Patients with at least one measurable lesion according to RECIST 1.
- •Males or non-pregnant, non-lactating, females.
- •Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
- •Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.
排除标准
- •Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event.
- •Patients with prior treatment with immune check-point inhibitors
- •Patients with prior exposure to EO
- •Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2401 administration.
- •Patients with an initial diagnosis of ACC less than 9 months from start of screening part
- •Patients with ACC and any individual lesion according to RECIST 1.1 having a maximum diameter of more than 125 mm; irrespective if the lesion is proposed as a target lesion, or not, according to RECIST 1.
- •Patients with ACC with more than three organs involved by disease, combined with unresectable primary tumor.
- •Patients with ACC and uncontrolled hormonal secretion (according to the judgement of the treating physician).
- •Patients with MPP and uncontrolled blood pressure (according to the judgement of the treating physician).
- •Patients with abnormal laboratory values.
- •Patients with persistent Grade 3 or 4 toxicities.
- •Uncontrolled central nervous system (CNS) metastasis.
- •Other malignancy or prior malignancy with a disease-free interval of less than 3 years
- •Patients with clinically significant disease.
- •Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).
- •Patients with history of solid organ transplantation or hematopoietic stem cell transplantation.
- •Patients with history or known presence of tuberculosis.
- •Pregnant and breastfeeding patients.
- •Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection.
- •Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug.
- •Patients with a history of hypersensitivity to any excipient present in the pharmaceutical forms of the study treatments.
- •Patients treated with herbal remedies with immunostimulating properties or known to potentially interfere with major organ function.
- •Patients with known ongoing drug and alcohol abuse.
- •Patients with known or underlying medical or psychiatric condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or AEs.
- •Patients deprived of their liberty, under protective custody, or guardship.
研究组 & 干预措施
5-cohort study design
Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.
Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma.
Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma.
干预措施: EO2401 (Biological)
5-cohort study design
Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.
Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma.
Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma.
干预措施: Nivolumab (Biological)
randomized extension of Cohort 2A (3 arms): C2A-I
Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
干预措施: EO2401 (Biological)
randomized extension of Cohort 2A (3 arms): C2A-I
Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
干预措施: Nivolumab (Biological)
randomized extension of Cohort 2A (3 arms): C2A-II
11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.
干预措施: EO2401 (Biological)
randomized extension of Cohort 2A (3 arms): C2A-III
11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.
干预措施: Nivolumab (Biological)
结局指标
主要结局
Treatment-Emergent Serious Adverse Events Assessment
时间窗: 46 months maximum (from baseline up to study end)
Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Treatment-Emergent Non-Serious Adverse Events
时间窗: 46 months maximum (from baseline up to study end)
Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
All Cause Mortalities Assessment
时间窗: 46 months maximum (from baseline up to study end)
Incidence of death
次要结局
- Evaluation of Progression Free Survival(6 months after treatment start)
- Evaluation of Survival(46 months maximum (from baseline up to study end))
- Percentage of Patients With Immunogenicity Against EO2401(7 weeks after treatment start)